RPS6KA3 and breast cancer: We have recently demonstrated that both FGFR2 and RSK2 were expressed in primary breast cancer samples and lack of combined immunoreactivity for FGFR2 and activated RSK (RSK-P) was predictive of a better patients’ disease-free survival [30].